Adamis Pharmaceuticals Corporation

Latest news

• FDA Approves Zimhi (naloxone hydrochloride) Injection for the Treatment of Opioid Overdose
  18 October 2021
• Adamis Provides Update on Zimhi
  9 June 2021
• Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA for the Treatment of Opioid Overdose
  17 May 2021
• Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding Zimhi
  16 November 2020
• Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA
  20 May 2020
• Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
  27 September 2018
• Adamis Pharmaceuticals Receives FDA Approval for Symjepi (epinephrine) Pre-Filled Syringe
  15 June 2017
• Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
  19 January 2017
• Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
  16 December 2016
• Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
  6 June 2016

Drugs Associated with Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.